Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

NEW INDICATIONS

Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On November 17, 2021, the FDA accelerated the approval of a new indication for pembrolizumab (Keytruda; Merck), for the adjuvant treatment of patients with renal-cell carcinoma (RCC) at intermediate-high or high risk for recurrence after nephrectomy or after nephrectomy and resection of metastatic lesions.

This approval was evaluated in the KEYNOTE-564 study, a multicenter, randomized, double-blind, placebo-controlled clinical trial of 994 patients with RCC at intermediate-high or high risk for recurrence, or for patients with no evidence of disease. The patients were randomized in a 1:1 ratio to pembrolizumab every 3 weeks or to placebo for up to 1 year, until disease recurrence or unacceptable adverse events.

The primary end point was investigator-assessed disease-free survival (DFS), defined as time to recurrence, metastasis, or death. The overall survival (OS) was a secondary end point. At a prespecified interim analysis, significant improvement in DFS was demonstrated, including 109 (22%) DFS events in the pembrolizumab arm and 151 (30%) DFS events in patients receiving placebo (hazard ratio, 0.68; 95% confidence interval, 0.53-0.87; P = .0010). The median DFS was not reached in either arm. At the time of the analysis, OS data were not mature, and 5% of deaths were reported in the overall population.

The most common (≥20%) adverse reactions to pembrolizumab in this study were musculoskeletal pain, fatigue, rash, diarrhea, pruritus, and hypothyroidism.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.